Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pulmonology
•
Obstructive Lung Disease
•
PFTs
Do you implement FEV3/FEV6 or FEF25-75 measurements in the evaluation of patients for small airways obstruction?
Related Questions
How do you mitigate the risk of inadverdent under or over diagnosis of COPD in certain populations with transition to race-neutral spirometry reference equations?
Do you routinely consider evaluation for EDAC in patients with asthma or COPD on maximal inhaler therapy who have refractory symptoms?
What is the rationale/evidence to support doing 4 puffs of albuterol vs. 2 puffs for a reversibility study?
What is your preferred rescue inhaler for patients with asthma?
Do you plan to use benralizumab to treat acute exacerbations of asthma or COPD associated with eosinophilia?
What is your approach to de-escalation of asthma inhaler therapy in the setting of negative bronchoprovocation testing when patients are averse to deprescribing?
How might the introduction of brensocatib as a treatment option impact the use of other anti- inflammatory or antibiotic therapies currently employed in bronchiectasis management?
Do you feel high dose Symbicort or Dulera is appropriate to use for SMART despite these doses not being studied in clinical trials?
What is your approach to de-escalation of asthma therapy if patients have remained clinically stable on triple inhaler therapy and a biologic agent?
What is your preferred biologic in children and adolescents with T2 high asthma?
